Cariprazine and Lumacaftor: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 16, 2026 · Source data updated Jul 16, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Lumacaftor
No brand names on recordCariprazine
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Here's what's going on. Lumacaftor speeds up a liver enzyme called CYP3A4. That same enzyme handles cariprazine (Vraylar), which is your mental-health medicine. What makes this tricky is that CYP3A4 both builds up and breaks down cariprazine's active forms, so when the enzyme runs faster, no one has fully studied whether you'd end up with too little or too much active drug in your body.
Because the outcome isn't clear, combining them is generally not recommended. Please don't stop or change either medicine on your own. Talk with your pharmacist or doctor. Your care team can look at your specific situation and choose the safest plan for you.
Mechanism: Lumacaftor is a CYP3A4 inducer; cariprazine is a CYP3A4 substrate. Notably, CYP3A4 mediates both the formation and the elimination of cariprazine's active metabolites (DCAR, DDCAR), so the net effect of induction on active-moiety exposure is unpredictable.
- Direction: Unclear (could reduce or shift active-metabolite exposure).
- Magnitude: Not quantified; not formally studied.
- Onset: Unspecified (enzyme induction is typically delayed, over days to weeks).
- Evidence: Theoretical.
- Management: Coadministration is not recommended. If unavoidable, monitor closely for loss of efficacy or altered response; individualize per care team.
What happens
Effects on the cariprazine exposure has not been evaluated and the net effect is unclear
Interaction Deep Dive
It is advised against giving cariprazine (which is metabolized by CYP3A4) together with a CYP3A4 inducer. The active metabolites of cariprazine are both produced and cleared via CYP3A4. How CYP3A4 inducers alter cariprazine exposure has not been studied, so the overall consequence remains uncertain1.
Why it happens (mechanism)
Induction of CYP3A4-mediated metabolism of cariprazine
How to manage this interaction
What your care team may do:
- Because the combined effect on cariprazine hasn't been studied, this pairing is generally not recommended, and your team may consider an alternative.
- If you do take both, expect closer monitoring for any change in how well your cariprazine is working or any new symptoms.
What you should do:
- Keep taking both exactly as prescribed unless your prescriber tells you otherwise.
- Tell your pharmacist and doctor that you take both, and mention any return of symptoms or unusual side effects. Your team can tailor the plan for you.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Cariprazine and Lumacaftor together?
Lumacaftor may speed up how your body processes cariprazine, and because the result is unpredictable, using them together isn't recommended. Don't change anything on your own; ask your pharmacist or doctor whether an alternative or closer monitoring is right for you. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Cariprazine and Lumacaftor interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Cariprazine and Lumacaftor interaction managed?
What your care team may do: Because the combined effect on cariprazine hasn't been studied, this pairing is generally not recommended, and your team may consider an alternative. If you do take both, expect closer monitoring for any change in how well your cariprazine is working or any new symptoms. What you should do: Keep taking both exactly as prescribed unless your prescriber tells you otherwis… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Cariprazine or Lumacaftor need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: VRAYLAR(R) oral capsules, cariprazine oral capsules. AbbVie Inc. (per FDA), North Chicago, IL, 2024. DailyMed
Keep reading about Lumacaftor
Keep reading about Cariprazine
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist